Creo Medical Group PLC Announces First Patient Treated with Speedboat (8135I)

TIDMCREO

RNS Number : 8135I

Creo Medical Group PLC

22 June 2017

Creo Medical Group plc

("Creo" or "the Company")

Creo Medical Announces First Patient Treated with Speedboat

Progression of first commercial product on track

Chepstow, South Wales - 22 June 2017 - Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, is pleased to announce the first clinical use of the Company's Speedboat device.

The first patient with a large pre-cancerous lesion in the gastrointestinal (GI) tract was treated using Creo's Speedboat device powered by Creo's CROMA electrosurgery advanced energy platform. The patient was treated by Professor Brian Saunders at St. Mark's Hospital in London, United Kingdom.

Craig Gulliford, Chief Executive Officer of Creo Medical, commented: "The first treatment of a patient is a significant inflection in the commercialisation of our first product from the endoscopic pipeline. In-line with our strategy, we are increasing surgeon training to expand clinical awareness and bring the benefits of this important new development to those patients in need. We have a complementary range of products in development and believe that this positions Creo well to become a leader in this growing billion dollar market. We look forward to treating more patients in the near future and sharing our experience with the wider clinical community."

The Speedboat device harnesses the precise cut and coagulation capability of CROMA to remove early cancerous and pre-cancerous lesions in the bowel. The use of the Speedboat device helps reduce the risks associated with alternative laparoscopic procedures, reducing the length of hospital stays and transferring therapy from the operating room to the endoscopy room.

Endoscopy has been a rapidly expanding practice due to the advent of colorectal cancer screening in most healthcare systems. This has driven growth in equipment and devices to enhance the ability to screen, detect and treat early stage and pre-cancerous lesions in the GI tract.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 
 Contacts 
 Creo Medical:                      Cenkos:            FTI Consulting: 
 Roseanne Varner                    Ivonne Cantu       Brett Pollard 
  [phone]                / Camilla Hume     / Mo Noonan 
  [e-mail]    (NOMAD)            [phone] 
                                     Michael Johnson    1000 
                                     / Russell Kerr     [e-mail] 
                                     (Sales) 
                                     [phone] 
                                     8900 
 

Notes to the Editors

About Speedboat

The Speedboat device will be utilised for removing lesions from inside the bowel using an endoscope. This approach can replace open or laparoscopic surgery as well as the alternative endoscopic approach of Endoscopic Mucosal Resection (EMR). EMR removes larger lesions in many pieces. This can lead to residual polyp being left behind, causing recurrence. With the Speedboat device, the Endoscopist is able to remove the lesion in a single large piece (en-bloc), providing a more complete and accurate specimen for analysis and reducing the need for frequent endoscopic checks.

About CROMA

Creo's advanced energy platform uniquely combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation, providing physicians with flexible, accurate and controlled surgical solutions through a single accessory port. This technology makes it possible to treat conditions using flexible endoscopy in the endoscopy suite as opposed to a surgical outcome carried out in the operating theatre under general anaesthetic. The Company's strategy is to bring the CROMA platform to market through a suite of medical devices which the Company has designed, initially into the emerging field of GI therapeutic endoscopy, and later into a broader range of areas including bronchoscopy and laparoscopy.

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring the CROMA surgical system to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

UPDLFFLIRIILFID

(END) Dow Jones Newswires

June 22, 2017 02:00 ET (06:00 GMT)